Navigation Links
Prolia® (Denosumab) Phase 2 Extension Study Showed Continued Increase in Bone Mineral Density Over Eight Years of Treatment
Date:9/17/2011

fracture; or patients who have failed or are intolerant to other available osteoporosis therapy.

Prolia is approved in the European Union (EU) for the treatment of osteoporosis in postmenopausal women at increased risk of fractures, and for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures.

Prolia is approved in the U.S., Canada, Australia and in all 27 EU member states as well as in Norway, Iceland and Liechtenstein. Applications in the rest of the world are pending.

Prolia is administered as a single subcutaneous injection of 60 mg once every six months. For further information on Prolia, including prescribing information and medication guide, please visit: www.prolia.com.  

Important U.S. Safety Information

Prolia is contraindicated in patients with hypocalcemia. Pre-existing hypocalcemia must be corrected prior to initiating Prolia. Hypocalcemia may worsen, especially in patients with severe renal impairment. All patients should be adequately supplemented with calcium and vitamin D. Patients receiving Prolia should not receive XGEVA® (denosumab), as both Prolia and XGEVA contain the same active ingredient, denosumab.

In the Phase 3 pivotal study, serious infections leading to hospitalizations were reported more frequently in the Prolia-treated patient group. Serious skin infections, as well as infections of the abdomen, urinary tract and ear, were more frequent in patients treated with Prolia. Patients should be advised to seek prompt medical attention if they develop signs or symptoms of severe infection, including cellulitis. Endocarditis was reported more frequently in the Prolia-treated patient group. Epidermal and dermal adverse events such as dermatitis, rashes and eczema have been reported. Discontinuation of Prolia should be considered if severe symptoms develop.

Prolia resulted
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Treatment With Prolia® (denosumab) Associated With Significantly Greater Adherence, Compliance and Persistence Compared to Alendronate
2. Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Five Years of Treatment With Similar Safety Profile Observed in Pivotal Trial
3. XGEVA® (Denosumab) Granted Marketing Authorization in the European Union
4. Amgen Receives CHMP Positive Opinion for XGEVA™ (Denosumab) in the European Union
5. Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer
6. The Journal of Clinical Oncology Publishes Phase 3 XGEVA™ (Denosumab) Results in Advanced Cancer Patients With Solid Tumors or Multiple Myeloma
7. XGEVA™ (Denosumab) Significantly Improved Bone Metastasis-Free Survival in Men With Prostate Cancer
8. Amgen Presents New XGEVA™ (Denosumab) Breast Cancer Skeletal-Related Event Prevention Data at SABCS
9. Prolia™ (denosumab) Receives Best New Drug Honor at Scrip Awards
10. Vantage Health Announces That All of Its Required Tanzanian Registrations, Permits and Licenses Have Been Formally Issued, Simultaneous With Official Notification That Its Application for Phase One Evaluation of Its HIV Screening Test Kits Has Been
11. Soligenix Announces Results of Recent Data Safety Monitoring Board Review for Phase 3 orBec® Study in Acute GI GVHD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... -- Vermillion, Inc. (NASDAQ: VRML ), a multivariate ... has appointed Holly B. Bauzon as Vice ... Bauzon has a proven track record in both increasing ... companies. She has more than 20 years of healthcare ... the position of Director, Lab Services Sales and Managed ...
(Date:8/21/2014)... 21, 2014 The spinal column is one of ... Signals carried to and from the brain through the column ... system. Injury or ailment here can be life altering, and ... of control over their body. Though back injury and disease ... there are more options available to make things better than ...
(Date:8/21/2014)... , Aug. 21, 2014 /CNW/ - The Canadian Epilepsy Alliance ... comic series designed to educate children about the most common ... Medikidz Explain Epilepsy comic series tells a fictional ... navigating middle school while living with epilepsy. ... there is still so much misinformation and lack of awareness ...
Breaking Medicine Technology:Vermillion Appoints Holly B. Bauzon as VP of Sales and Managed Markets 2Don't Live in Pain: Four Life Improving Benefits of Back Surgery 2Action Heroes Harness Powers to Educate Children About Epilepsy 2Action Heroes Harness Powers to Educate Children About Epilepsy 3
... , MINNEAPOLIS, Dec. 29 Target® announces ... seven Target Clinic locations in Maryland, while supplies last. ... will be available daily at Target Clinic locations during clinic ... cover the cost). For information on which stores ...
... , , MOUNTAIN VIEW, Calif., Dec. 29 ... developing innovative, next-generation medical therapies to address unmet needs in ... Drug Application (NDA) has been submitted to the U.S. Food ... drug for the treatment of obesity, including weight loss and ...
Cached Medicine Technology:VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity 2VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity 3VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity 4VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity 5
(Date:8/23/2014)... Albany, New York (PRWEB) August 23, 2014 ... invasive surgeries done to remove plaques, etc, thereby addressing ... surgeries restore the flow of blood to the other ... the flow of oxygenated blood. These procedures require the ... made of metal composites and polymers), these catheters are ...
(Date:8/23/2014)... PA (PRWEB) August 23, 2014 Having been ... and dental hygienist from Arlington, Texas, saw a need for ... and toothpaste. "That’s when I came up with the idea ... No-Brush provides an effective way for a user to clean ... need to carry multiple items. It also helps avoid plaque ...
(Date:8/23/2014)... (PRWEB) August 23, 2014 A team of ... mesothelioma last longer when preceded by surgery and delivered by ... on the new study. Click here to read it ... studied the cases of mesothelioma patients who underwent ... conforming radiotherapy dose to the shape of a tumor. ...
(Date:8/23/2014)... August 23, 2014 Legal Insider ... created by Greg Marks has been generating a buzz ... month. The commotion surrounding the new product has drawn ... review. , “In recent years the market ... systems, commonly referred to as robots or ‘bots,'” reports ...
(Date:8/23/2014)... GBI Research, the leading business intelligence ... in Major Developed Markets to 2020 - New and ... which provides in-depth analysis of the critical care market ... and Canada. The report provides an estimation of market ... It covers critical care indications that are being treated ...
Breaking Medicine News(10 mins):Health News:Global Peripheral Intervention Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Health News:Global Peripheral Intervention Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Health News:Global Peripheral Intervention Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 4Health News:New Study Links Hospital Experience and Prior Surgery with Mesothelioma Radiation Success, According to Surviving Mesothelioma 2Health News:Legal Insider Bot Review Examining Greg Marks’ Trading Software Released 2Health News:Critical Care Therapeutics in Major Developed Markets to 2020 | Researchmoz 2Health News:Critical Care Therapeutics in Major Developed Markets to 2020 | Researchmoz 3
... Southeast Florida Market, NORTH HOLLYWOOD, Calif., Aug. ... IPCM ), a leading national hospitalist,physician group practice, ... of Hospitalists of America (HOA). The acquisition,expands IPC,s ... with a network of independent physicians, who perform ...
... InteKrin Therapeutics, Inc.,a clinical stage biopharmaceutical company ... and obesity today announced it has,completed the first ... $18.25,million. The financing was led by Skyline Ventures ... Ph.D. of Skyline will join InteKrin,s Board of,Directors. ...
... (Nasdaq:,EVVV), a global endovascular device company, today announced the,appointment ... effective,immediately. Mr. Kohrs will also serve as a member ... director of ev3 from June 2005,until October 2007 at ... the completion of ev3,s acquisition of FoxHollow Technologies,Inc., ...
... the Virginia Bioinformatics Institute (VBI) at Virginia Tech have ... proteins in oomycete plant pathogens that enables the proteins ... region contains the amino acid sequence motifs RXLR and ... proteins across the membrane surrounding plant cells without any ...
... less rest linked to doubled chance of weight gain, study ... little sleep or not spending enough time in rapid eye ... and teens, a new U.S. study. , For three consecutive ... 7 to 17. They looked at total sleep time, time ...
... Study finds that older patients, concerns often go unspoken and ... ... surgery with,their orthopaedic surgeons, older patients frequently do not raise all of,their ... The Journal of Bone and Joint Surgery found that patients age,60 or ...
Cached Medicine News:Health News:IPC The Hospitalist Company Completes Acquisition of Hospitalists of America 2Health News:InteKrin Therapeutics Announces $20 Million Series C Financing 2Health News:ev3 Inc. Appoints Douglas W. Kohrs to Board of Directors 2Health News:Key to virulence protein entry into host cells discovered 2Health News:Kids Who Sleep Poorly at Risk for Being Overweight 2Health News:Video: Communication is Key to Ease Worry about Orthopaedic Surgery 2Health News:Video: Communication is Key to Ease Worry about Orthopaedic Surgery 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: